WHO ICTRP trial
The feasibility of dendritic cell-based immunotherapy targeting synthesized long…
JPRN-UMIN000014435 · Japan Primary Registries Network (JPRN) · Not Recruiting
Key facts
| Trial ID | JPRN-UMIN000014435 |
|---|---|
| Public title | The feasibility of dendritic cell-based immunotherapy targeting synthesized long peptides containing helper epitopes for malignant tumor. |
| Scientific title | The feasibility of dendritic cell-based immunotherapy targeting synthesized long peptides containing helper epitopes for malignant tumor. - The feasibility of dendritic cell-based immunotherapy targeting synthesized long peptides for malignant tumor. |
| Primary sponsor | Medical Corporation Isokai Seren Clinic Tokyo |
| Registry | Japan Primary Registries Network (JPRN) |
| Recruitment status | Not Recruiting |
| Study type | Interventional |
| Phase | Phase I |
| Countries | Japan |
| Conditions | Malignant tumor |
| Interventions | All patients are intradermally injected 5-7 times with dendritic cells in close proximity to the axial and/or inguinal lymph nodes. Injections are repeated every 14-21 days. |
| Registration date | Jun 30, 2014 |
| Target size | 10 |
| Registry page | center6.umin.ac.jp |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: